B. Douglas Smith

11.3k total citations · 1 hit paper
171 papers, 6.3k citations indexed

About

B. Douglas Smith is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, B. Douglas Smith has authored 171 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Hematology, 67 papers in Molecular Biology and 45 papers in Genetics. Recurrent topics in B. Douglas Smith's work include Acute Myeloid Leukemia Research (95 papers), Chronic Myeloid Leukemia Treatments (41 papers) and Chronic Lymphocytic Leukemia Research (32 papers). B. Douglas Smith is often cited by papers focused on Acute Myeloid Leukemia Research (95 papers), Chronic Myeloid Leukemia Treatments (41 papers) and Chronic Lymphocytic Leukemia Research (32 papers). B. Douglas Smith collaborates with scholars based in United States, Germany and Italy. B. Douglas Smith's co-authors include Mark J. Levis, Donald Small, Judith E. Karp, Richard J. Jones, William Matsui, Kathleen M. Murphy, Karin D. Berg, Hagop M. Kantarjian, Robert A. Brodsky and Scott H. Kaufmann and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

B. Douglas Smith

166 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

2018 354 citations Jörge E. Cortes, B. Douglas Smith et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B. Douglas Smith United States	43	4.2k	2.8k	1.5k	1.3k	947	171	6.3k
Eric J. Feldman United States	42	4.3k 1.0×	3.0k 1.0×	1.8k 1.2×	1.4k 1.1×	933 1.0×	195	6.7k
William Blum United States	43	2.7k 0.7×	2.5k 0.9×	1.1k 0.7×	1.3k 1.0×	667 0.7×	188	5.6k
Jeffrey E. Lancet United States	48	5.3k 1.3×	3.5k 1.2×	2.1k 1.4×	1.8k 1.4×	1.0k 1.1×	437	7.8k
Ilene Galinsky United States	32	3.3k 0.8×	2.6k 0.9×	1.9k 1.2×	969 0.7×	581 0.6×	84	5.3k
Martin Höglund Sweden	37	3.4k 0.8×	1.5k 0.5×	1.6k 1.0×	1.2k 0.9×	1.1k 1.2×	134	5.1k
Steven D. Gore United States	44	6.2k 1.5×	3.6k 1.3×	2.1k 1.4×	1.2k 0.9×	1.4k 1.5×	226	8.1k
Keith W. Pratz United States	33	4.2k 1.0×	2.5k 0.9×	1.4k 0.9×	962 0.7×	917 1.0×	128	5.2k
Alexander E. Perl United States	37	3.9k 0.9×	3.2k 1.1×	1.6k 1.0×	942 0.7×	744 0.8×	200	6.3k
Daniel A. Pollyea United States	44	6.0k 1.4×	4.6k 1.6×	1.6k 1.1×	1.4k 1.1×	1.2k 1.3×	211	8.4k
Virginia M. Klimek United States	26	2.8k 0.7×	3.1k 1.1×	981 0.6×	871 0.6×	537 0.6×	78	5.1k

Countries citing papers authored by B. Douglas Smith

Since Specialization

Citations

This map shows the geographic impact of B. Douglas Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Douglas Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Douglas Smith more than expected).

Fields of papers citing papers by B. Douglas Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Douglas Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Douglas Smith. The network helps show where B. Douglas Smith may publish in the future.

Co-authorship network of co-authors of B. Douglas Smith

This figure shows the co-authorship network connecting the top 25 collaborators of B. Douglas Smith. A scholar is included among the top collaborators of B. Douglas Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Douglas Smith. B. Douglas Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mo, Shirley, Alexander J. Ambinder, Amy E. DeZern, et al.. (2025). DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors. Blood. 146(Supplement 1). 1710–1710.

Webster, Jonathan, Mark J. Levis, Ivana Gojo, et al.. (2025). Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML. PubMed. 2(4). 100133–100133. 1 indexed citations

Smith, B. Douglas, Tim H. Brümmendorf, Gail J. Roboz, et al.. (2024). Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study. Leukemia Research. 139. 107481–107481. 1 indexed citations

Li, Daniel, B. Douglas Smith, Mark J. Levis, et al.. (2024). Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias. Blood. 144(Supplement 1). 5904–5904.

Karantanos, Theodoros, Hua‐Ling Tsai, Lukasz P. Gondek, et al.. (2022). Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. Leukemia & lymphoma. 63(8). 1942–1948. 8 indexed citations

Sweet, Kendra, Jörge E. Cortes, Jane F. Apperley, et al.. (2022). Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia. Clinical Cancer Research. 29(12). 2179–2183. 1 indexed citations

Webster, Jonathan, Tara M. Robinson, Amanda L. Blackford, et al.. (2021). A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. Leukemia Research. 111. 106737–106737. 4 indexed citations

Carraway, Hetty E., Yazeed Sawalha, Ivana Gojo, et al.. (2021). Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. Leukemia Research. 110. 106707–106707. 10 indexed citations

Zeidner, Joshua F., Daniel J. Lee, Mark G. Frattini, et al.. (2020). Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia. Clinical Cancer Research. 27(1). 60–69. 18 indexed citations

10.

Dalton, W. Brian, Bing Li, Christopher D. Gocke, et al.. (2020). The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. Blood Advances. 4(7). 1192–1196. 38 indexed citations

11.

Cortes, Jörge E., Carla Mamolo, Joseph C. Cappelleri, et al.. (2019). Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. Current Medical Research and Opinion. 35(9). 1615–1622. 12 indexed citations

12.

Zeidan, Amer M., Hanna A. Knaus, Tara M. Robinson, et al.. (2018). A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clinical Cancer Research. 24(15). 3519–3527. 74 indexed citations

13.

Pratz, Keith W., Michelle A. Rudek, Ivana Gojo, et al.. (2016). A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. Clinical Cancer Research. 23(4). 899–907. 38 indexed citations

14.

Pratz, Keith W., Brian D. Koh, Anand G. Patel, et al.. (2016). Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. Clinical Cancer Research. 22(15). 3894–3902. 23 indexed citations

15.

Schenk, Erin L., Brian D. Koh, Karen S. Flatten, et al.. (2012). Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro. Clinical Cancer Research. 18(19). 5364–5373. 43 indexed citations

16.

Smith, B. Douglas, Yvette L. Kasamon, Jeanne Kowalski, et al.. (2010). K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate. Clinical Cancer Research. 16(1). 338–347. 77 indexed citations

17.

Hendrickson, Andrea E. Wahner, Paul Haluska, Paula A. Schneider, et al.. (2009). Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro. Cancer Research. 69(19). 7635–7643. 43 indexed citations

18.

Ye, Ying, Michael A. McDevitt, Mingzhou Guo, et al.. (2009). Progressive Chromatin Repression and Promoter Methylation of CTNNA1 Associated with Advanced Myeloid Malignancies. Cancer Research. 69(21). 8482–8490. 35 indexed citations

19.

El‐Shami, Khaled, Richard M. Stone, & B. Douglas Smith. (2008). FLT3 inhibitors in acute myeloid leukemia. Expert Review of Hematology. 1(2). 153–160. 7 indexed citations

20.

Matsui, William, Qiuju Wang, Sarah Brennan, et al.. (2007). The novel telomerase inhibitor GRN163L targets drug-resistant cancer stem cells in multiple myeloma. Molecular Cancer Therapeutics. 6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact